NASDAQ:ASBP Aspire Biopharma (ASBP) Stock Price, News & Analysis $8.80 0.00 (0.00%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$8.87 +0.07 (+0.84%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Aspire Biopharma Stock (NASDAQ:ASBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aspire Biopharma alerts:Sign Up Key Stats Today's Range$8.67▼$8.8650-Day Range$7.64▼$9.2552-Week Range$3.31▼$562.92Volume14,810 shsAverage Volume31,339 shsMarket Capitalization$12.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aspire Biopharma, Inc. is a biotechnology company focused on developing rapid drug-delivery technologies and pharmaceutical products. The company’s platform is designed to administer medications through the sublingual and buccal tissues of the mouth, with the goal of enabling faster absorption than conventional oral tablets. Aspire Biopharma’s lead product candidate is an orally delivered, fast-acting aspirin formulation intended for potential use in cardiovascular emergencies and other situations in which rapid aspirin administration may be beneficial. The company has also described its delivery platform as potentially adaptable to other medicines, although its development programs remain subject to clinical, regulatory and commercial requirements. The company’s operations are centered on advancing its drug-delivery platform and related product candidates through development and regulatory processes. Publicly available information provides limited detail regarding its broader geographic operations and leadership history.AI Generated. May Contain Errors. Read More Aspire Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreASBP MarketRank™: 0.45300878972 of 5 starsAspire Biopharma scored higher than 9% of companies evaluated by MarketBeat, and ranked 464th out of 480 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAspire Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Aspire Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aspire Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aspire Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.03% of the float of Aspire Biopharma has been sold short.Short Interest Ratio / Days to CoverAspire Biopharma has a short interest ratio ("days to cover") of 0.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aspire Biopharma has recently decreased by 60.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAspire Biopharma does not currently pay a dividend.Dividend GrowthAspire Biopharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Aspire Biopharma this week, compared to 2 articles on an average week.Search Interest1 people have searched for ASBP on MarketBeat in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aspire Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Aspire Biopharma is held by insiders.Percentage Held by Institutions19.17% of the stock of Aspire Biopharma is held by institutions.Read more about Aspire Biopharma's insider trading history. Receive ASBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aspire Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASBP Stock News HeadlinesKnorr-Bremse (OTCMKTS:KNRRY) and Aspire Biopharma (NASDAQ:ASBP) Head-To-Head AnalysisOctober 22, 2026 | americanbankingnews.comAspire-Lakewood Launches $10 Million Share Repurchase ProgramSeptember 9, 2026 | tipranks.comElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as January 27, and lays out what both men see coming in a short presentation. | Paradigm Press (Ad)Aspire Biopharma Holdings, Inc.: Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase ProgramSeptember 9, 2026 | finanznachrichten.deAspire Biopharma Changes Name to Aspire-Lakewood Holdings Inc.September 8, 2026 | usatoday.comAspire Biopharma Renamed Aspire-Lakewood Holdings, Inc.September 8, 2026 | tipranks.comAspire Biopharma Holdings Inc ASBPAugust 18, 2026 | morningstar.comMAspire Biopharma Holdings, Inc.: Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMBJuly 21, 2026 | finanznachrichten.deSee More Headlines ASBP Stock Analysis - Frequently Asked Questions How have ASBP shares performed this year? Aspire Biopharma's stock was trading at $158.28 at the beginning of 2026. Since then, ASBP stock has decreased by 94.4% and is now trading at $8.80. How were Aspire Biopharma's earnings last quarter? Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) announced its earnings results on Friday, November, 14th. The company reported ($48.00) earnings per share (EPS) for the quarter. The business earned $0 million during the quarter. When did Aspire Biopharma's stock split? Aspire Biopharma's stock reverse split on Monday, May 11th 2026.The 1-30 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aspire Biopharma? Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/14/2025Today10/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Automobile Components Sub-IndustryAutomotive Parts & Equipment Current SymbolNASDAQ:ASBP Previous SymbolNASDAQ:PWUP CIK1847345 Webaspirebiolabs.com Phone(561) 704-8527FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($69.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.48 million Net Margins-11,362.21% Pretax Margin-11,361.18% Return on EquityN/A Return on Assets-177.59% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.82 Sales & Book Value Annual Sales$10 thousand Price / Sales1,232.00 Cash FlowN/A Price / Cash FlowN/A Book Value($54.19) per share Price / Book-0.16Miscellaneous Outstanding Shares1,400,000Free Float1,322,000Market Cap$12.32 million OptionableN/A Beta0.17 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ASBP) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredFinally… options made simpleIan Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...TradeWins | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
